122 related articles for article (PubMed ID: 20575022)
1. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.
Sharma M; Qureshi SR; Champlin RE; Popat U; Giralt S; Qazilbash MH
Am J Hematol; 2010 Jul; 85(7):502-4. PubMed ID: 20575022
[TBL] [Abstract][Full Text] [Related]
2. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
Lawless S; Sbianchi G; Morris C; Iacobelli S; Bosman P; Blaise D; Reményi P; Byrne JL; Mayer J; Apperley J; Lund J; Kobbe G; Schaap N; Isaksson C; Lenhoff S; Basak G; Touzeau C; Wilson KMO; González Muñiz S; Scheid C; Browne P; Anagnostopoulos A; Rambaldi A; Jantunen E; Kröger N; Schönland S; Yakoub-Agha I; Garderet L
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):686-693. PubMed ID: 34158265
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
Reece DE; Vesole DH; Shrestha S; Zhang MJ; Pérez WS; Dispenzieri A; Milone GA; Abidi M; Atkins H; Bashey A; Bredeson CN; Boza WB; Freytes CO; Gale RP; Gajewski JL; Gibson J; Hale GA; Kumar S; Kyle RA; Lazarus HM; McCarthy PL; Pavlovsky S; Roy V; Weisdorf DJ; Wiernik PH; Hari PN
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):458-63. PubMed ID: 21156462
[TBL] [Abstract][Full Text] [Related]
4. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
6. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma.
Maisnar V; Hájek R; Scudla V; Gregora E; Büchler T; Tichý M; Kotoucek P; Kafková A; Forraiová L; Minarík J; Radocha J; Bláha V; Malý J
Bone Marrow Transplant; 2008 Jan; 41(1):51-4. PubMed ID: 17934529
[TBL] [Abstract][Full Text] [Related]
8. Durable remission with salvage second autotransplants in patients with multiple myeloma.
Shah N; Ahmed F; Bashir Q; Qureshi S; Dinh Y; Rondon G; Wen S; Thall P; Khan H; Giralt S; Champlin R; Qazilbash MH
Cancer; 2012 Jul; 118(14):3549-55. PubMed ID: 22086552
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.
Kang J; Hong JY; Yoon DH; Kim S; Lee KM; Park JS; Park CJ; Min WK; Seo EJ; Jang S; Suh C
Acta Haematol; 2018; 139(3):185-192. PubMed ID: 29635247
[TBL] [Abstract][Full Text] [Related]
10. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
[TBL] [Abstract][Full Text] [Related]
11. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.
Pisani F; Petrucci MT; Giannarelli D; Bongarzoni V; Montanaro M; De Stefano V; La Verde G; Gentilini F; Levi A; Za T; Moscetti A; Annino L; Petti MC;
J Exp Clin Cancer Res; 2012 Mar; 31(1):17. PubMed ID: 22381082
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
14. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
Vesole DH; Zhang L; Flomenberg N; Greipp PR; Lazarus HM; Huff CA;
Biol Blood Marrow Transplant; 2009 Jan; 15(1):83-91. PubMed ID: 19135946
[TBL] [Abstract][Full Text] [Related]
18. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
Nakasone H; Terasako-Saito K; Hirano T; Wake A; Shimizu S; Kurita N; Yamazaki E; Usuki K; Akazawa K; Kanda J; Minauchi K; Yamamoto G; Tanimoto S; Kamoshita M; Yokoyama Y; Miyaoka E; Ota S; Kako S; Izutsu K; Kanda Y
Hematol Oncol; 2018 Feb; 36(1):202-209. PubMed ID: 28681529
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
20. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
